Long Non-Coding Rnas and Melanoma: From Diagnosis to Therapy Publisher Pubmed



Dashti F^{1, 2} ; Mirazimi SMA^{1, 2} ; Kazemioula G³ ; Mohammadi M⁴ ; Hosseini M⁵ ; Razaghi Bahabadi Z^{1, 2} ; Mirazimi MS⁶ ; Abadi MHJN⁷ ; Shahini A⁸ ; Afshari M⁹ ; Mirzaei H¹⁰ Show Affiliations
Source: Pathology Research and Practice Published:2023

Abstract

Although extremely rare, malignant melanoma is the deadliest type of skin malignancy with the inherent capability to invade other organs and metastasize to distant tissues. In 2021, it was estimated that approximately 106,110 patients may have received the diagnosis of melanoma, with a mortality rate of 7180. Surgery remains the common choice for treatment in patients with melanoma. Despite many advances in the treatment of melanoma, some patients, such as those who have received cytotoxic chemotherapeutic and immunotherapic agents, a significant number of patients may show inadequate treatment response following initiating these treatments. Non-coding RNAs, including lncRNAs, have become recently popular and attracted the attention of many researchers to make new insights into the pathogenesis of many diseases, particularly malignancies. LncRNAs have been thoroughly investigated in multiple cancers such as melanoma and have been shown to play a major role in regulating various physiological and pathological cellular processes. Considering their core regulatory function, these non-coding RNAs may be appropriate candidates for melanoma patients' diagnosis, prognosis, and treatment. In this review, we will cover all the current literature available for lncRNAs in melanoma and will discuss their potential benefits as diagnostic and/or prognostic markers or potent therapeutic targets in the treatment of melanoma patients. © 2022 Elsevier GmbH